

Peter John Selby

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4206619/publications.pdf>

Version: 2024-02-01

79
papers

4,763
citations

147801

31
h-index

106344

65
g-index

81
all docs

81
docs citations

81
times ranked

7738
citing authors

#	ARTICLE	IF	CITATIONS
1	Stability of health-related quality of life and morbidity burden from 18 months after diagnosis of prostate cancer: results of a UK-wide population-based outcome cohort. <i>Supportive Care in Cancer</i> , 2022, 30, 3151-3164.	2.2	1
2	Abstract LB113: Genomic classification to refine prognosis in clear cell renal cell carcinoma. <i>Cancer Research</i> , 2022, 82, LB113-LB113.	0.9	0
3	Implementing the European Code of Cancer Practice to Improve Europe's Cancer Outcomes. <i>Touch Reviews in Oncology & Haematology</i> , 2021, 17, 9.	0.2	1
4	Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy. <i>Nature Communications</i> , 2021, 12, 1930.	12.8	7
5	The European Code of Cancer Practice. <i>Journal of Cancer Policy</i> , 2021, 28, 100282.	1.4	22
6	Do Learning Disabilities Affect Testicular Cancer Survival: A National Cohort Study Between 2001 and 2015. <i>European Urology Oncology</i> , 2020, 3, 773-779.	5.4	7
7	UK Multicenter Prospective Evaluation of the Leibovich Score in Localized Renal Cell Carcinoma: Performance has Altered Over Time. <i>Urology</i> , 2020, 136, 162-168.	1.0	12
8	Influence of deprivation and rurality on patient-reported outcomes of men living with and beyond prostate cancer diagnosis in the UK: A population-based study. <i>Cancer Epidemiology</i> , 2020, 69, 101830.	1.9	6
9	Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer. <i>BMJ Open</i> , 2020, 10, e035938.	1.9	54
10	Dysregulation at multiple points of the kynurenine pathway is a ubiquitous feature of renal cancer: implications for tumour immune evasion. <i>British Journal of Cancer</i> , 2020, 123, 137-147.	6.4	17
11	APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy. <i>Nature Communications</i> , 2020, 11, 790.	12.8	47
12	Decision regret in men living with and beyond nonmetastatic prostate cancer in the United Kingdom: A population-based patient-reported outcome study. <i>Psycho-Oncology</i> , 2020, 29, 886-893.	2.3	26
13	AUTHOR REPLY. <i>Urology</i> , 2020, 136, 168.	1.0	0
14	ECCO Essential Requirements for Quality Cancer Care: Prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 148, 102861.	4.4	29
15	Cancer-related symptoms, mental well-being, and psychological distress in men diagnosed with prostate cancer treated with androgen deprivation therapy. <i>Quality of Life Research</i> , 2019, 28, 2741-2751.	3.1	21
16	Sex specific associations in genome wide association analysis of renal cell carcinoma. <i>European Journal of Human Genetics</i> , 2019, 27, 1589-1598.	2.8	27
17	ECCO Essential Requirements for Quality Cancer Care: Primary care. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 187-199.	4.4	15
18	Rectal cancer in old age "is it appropriately managed? Evidence from population-based analysis of routine data across the English national health service. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1196-1204.	1.0	20

#	ARTICLE	IF	CITATIONS
19	Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study. <i>Lancet Oncology</i> , The, 2019, 20, 436-447.	10.7	100
20	Regional Variations in Quality of Survival Among Men with Prostate Cancer Across the United Kingdom. <i>European Urology</i> , 2019, 76, 228-237.	1.9	6
21	The Value and Future Developments of Multidisciplinary Team Cancer Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 332-340.	3.8	93
22	Key factors associated with social distress after prostate cancer: Results from the United Kingdom Life after Prostate Cancer diagnosis study. <i>Cancer Epidemiology</i> , 2019, 60, 201-207.	1.9	15
23	How can clinical research improve European health outcomes in cancer?. <i>Journal of Cancer Policy</i> , 2019, 20, 100182.	1.4	10
24	Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment. <i>Cancer Immunology Research</i> , 2019, 7, 828-840.	3.4	13
25	Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer. <i>Journal of Pathology</i> , 2019, 247, 381-391.	4.5	33
26	Urinary, bowel and sexual health in older men from Northern Ireland. <i>BJU International</i> , 2018, 122, 845-857.	2.5	18
27	Mapping the cancer patient information landscape: A comparative analysis of patient groups across Europe and North America. <i>European Journal of Cancer</i> , 2018, 92, 88-95.	2.8	3
28	Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	288
29	Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer. <i>Gut</i> , 2018, 67, 562-573.	12.1	49
30	The impact of Brexit on UK cancer research. <i>Lancet Oncology</i> , The, 2018, 19, 1276-1278.	10.7	3
31	APOBEC3 Mediates Resistance to Oncolytic Viral Therapy. <i>Molecular Therapy - Oncolytics</i> , 2018, 11, 1-13.	4.4	14
32	Renal Cell Carcinoma Perfusion before and after Radiofrequency Ablation Measured with Dynamic Contrast Enhanced MRI: A Pilot Study. <i>Diagnostics</i> , 2018, 8, 3.	2.6	6
33	Taking patient reported outcomes centre stage in cancer research – why has it taken so long?. <i>Research Involvement and Engagement</i> , 2018, 4, 25.	2.9	25
34	High hospital research participation and improved colorectal cancer survival outcomes: a population-based study. <i>Gut</i> , 2017, 66, 89-96.	12.1	107
35	Genome-wide association study identifies multiple risk loci for renal cell carcinoma. <i>Nature Communications</i> , 2017, 8, 15724.	12.8	106
36	Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion. <i>Molecular Therapy - Oncolytics</i> , 2017, 5, 75-86.	4.4	22

#	ARTICLE	IF	CITATIONS
37	Subversion of NK-cell and TNFÎ± Immune Surveillance Drives Tumor Recurrence. <i>Cancer Immunology Research</i> , 2017, 5, 1029-1045.	3.4	22
38	Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. <i>European Urology</i> , 2017, 72, 747-754.	1.9	39
39	The Consequences for Cancer Care and Cancer Research of Brexit. <i>Ecancermedalscience</i> , 2017, 11, ed63.	1.1	2
40	An Association of Cancer Physiciansâ€™ strategy for improving services and outcomes for cancer patients. <i>Ecancermedalscience</i> , 2016, 10, 608.	1.1	5
41	The Association of Cancer Physicians responds to â€œCancer drugs, survival, and ethicsâ€. <i>BMJ, The</i> , 2016, 355, i6487.	6.0	3
42	Immunogenicity of self tumor associated proteins is enhanced through protein truncation. <i>Molecular Therapy - Oncolytics</i> , 2016, 3, 16030.	4.4	3
43	Responding to Acute Care Needs of Patients With Cancer: Recent Trends Across Continents. <i>Oncologist</i> , 2016, 21, 301-307.	3.7	29
44	The EU: what's best for UK cancer research and patients?. <i>Lancet Oncology, The</i> , 2016, 17, 556-557.	10.7	7
45	Life after prostate cancer diagnosis: protocol for a UK-wide patient-reported outcomes study. <i>BMJ Open</i> , 2016, 6, e013555.	1.9	27
46	Comment on â€˜an Association of Cancer Physiciansâ€™ strategy for improving services and outcomes for cancer patientsâ€™. <i>British Journal of Cancer</i> , 2016, 115, e1-e1.	6.4	1
47	The European Cancer Patientâ€™s Bill of Rights, update and implementation 2016. <i>ESMO Open</i> , 2016, 1, e000127.	4.5	36
48	CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	6.3	75
49	Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. <i>Neuro-Oncology</i> , 2016, 18, 518-527.	1.2	57
50	Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory Agents. <i>Molecular Therapy</i> , 2015, 23, 845-856.	8.2	11
51	A Rac/Cdc42 exchange factor complex promotes formation of lateral filopodia and blood vessel lumen morphogenesis. <i>Nature Communications</i> , 2015, 6, 7286.	12.8	66
52	Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma. <i>Journal of General Virology</i> , 2015, 96, 1533-1550.	2.9	30
53	Ageism in cancer care. <i>BMJ, The</i> , 2014, 348, g1614-g1614.	6.0	56
54	Cytokine Conditioning Enhances Systemic Delivery and Therapy of an Oncolytic Virus. <i>Molecular Therapy</i> , 2014, 22, 1851-1863.	8.2	60

#	ARTICLE	IF	CITATIONS
55	A Catalyst for Change: The European Cancer Patient's Bill of Rights. <i>Oncologist</i> , 2014, 19, 217-224.	3.7	35
56	Variation in genomic landscape of clear cell renal cell carcinoma across Europe. <i>Nature Communications</i> , 2014, 5, 5135.	12.8	158
57	A Bill of Rights for patients with cancer in Europe. <i>Lancet Oncology</i> , The, 2014, 15, 258-260.	10.7	26
58	Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells. <i>International Journal of Cancer</i> , 2013, 132, 2327-2338.	5.1	53
59	Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence. <i>Nature Medicine</i> , 2013, 19, 1625-1631.	30.7	52
60	The Royal College of Physicians Simms Lecture, 6 December 2011: Clinical research networks and the benefits of intensive healthcare systems. <i>Clinical Medicine</i> , 2012, 12, 446-452.	1.9	7
61	Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients. <i>Science Translational Medicine</i> , 2012, 4, 138ra77.	12.4	142
62	A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. <i>Human Molecular Genetics</i> , 2012, 21, 456-462.	2.9	81
63	Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. <i>Nature Genetics</i> , 2011, 43, 60-65.	21.4	220
64	Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF- κ B mediated and supports innate and adaptive anti-tumour immune priming. <i>Molecular Cancer</i> , 2011, 10, 20.	19.2	64
65	Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication. <i>Clinical Cancer Research</i> , 2009, 15, 4374-4381.	7.0	150
66	Multiple Myeloma Generates Regulatory T-Cells in a Contact-Dependent Manner Independent of TGF-Beta and IL-10. <i>Blood</i> , 2009, 114, 2835-2835.	1.4	0
67	Unravelling Biological Pathways and the Identification of Clinical Markers and Targets in Renal Cancer. , 2004, , 73-96.		0
68	Measuring Quality of Life in Routine Oncology Practice Improves Communication and Patient Well-Being: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 714-724.	1.6	1,160
69	Renal carcinoma cell lines inhibit natural killer activity via the CD94 receptor molecule. <i>Cancer Immunology, Immunotherapy</i> , 2001, 50, 260-268.	4.2	13
70	The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. <i>British Journal of Haematology</i> , 2001, 112, 814-819.	2.5	103
71	Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma. <i>Medical and Pediatric Oncology</i> , 2001, 36, 213-219.	1.0	40
72	Persistence of clonal T-cell expansions following high-dose chemotherapy and autologous peripheral blood progenitor cell rescue. <i>British Journal of Haematology</i> , 2000, 111, 766-773.	2.5	2

#	ARTICLE	IF	CITATIONS
73	Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. <i>British Journal of Haematology</i> , 1999, 104, 605-611.	2.5	79
74	The potential use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis – Preliminary findings. <i>Electrophoresis</i> , 1999, 20, 689-700.	2.4	287
75	Urological malignancies and the proteomic-genomic interface. <i>Electrophoresis</i> , 1999, 20, 3629-3637.	2.4	22
76	Urological malignancies and the proteomic-genomic interface. <i>Electrophoresis</i> , 1999, 20, 3629-3637.	2.4	2
77	Detection of colorectal cancer cells in peripheral blood by reverse-transcriptase polymerase chain reaction for cytokeratin 20. , 1998, 79, 288-293.		110
78	Detection of colorectal cancer cells in peripheral blood by reverse-transcriptase polymerase chain reaction for cytokeratin 20. <i>International Journal of Cancer</i> , 1998, 79, 288-293.	5.1	2
79	Patterns of splice variant CD44 expression by normal human urothelium in situ and in vitro and by bladder-carcinoma cell lines. <i>International Journal of Cancer</i> , 1995, 62, 449-456.	5.1	43